NASDAQ:NVNO

enVVeno Medical (NVNO) Stock Forecast, Price & News

$3.16

+0.19 (+6.40%)

(As of 06/2/2023 ET)

Compare

Today's Range: $2.87
▼
$3.17
50-Day Range: $2.91
▼
$5.19
52-Week Range: $2.83
▼
$7.93

Volume: 45,519 shs
Average Volume: 51,673 shs
Market Capitalization: $29.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About enVVeno Medical (NASDAQ:NVNO) Stock

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Receive NVNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter.

NVNO Stock News Headlines

May 1, 2023 | benzinga.com

enVVeno Medical Q1 2023 Ended Quarter With $34.2M In Cash

May 1, 2023 | finance.yahoo.com

enVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate Update

June 4, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

April 30, 2023 | americanbankingnews.com

enVVeno Medical (NASDAQ:NVNO) Trading Down 3.5%

March 22, 2023 | americanbankingnews.com

Contrasting enVVeno Medical (NASDAQ:NVNO) & Invo Bioscience (OTCMKTS:IVOB)

March 4, 2023 | finanznachrichten.de

enVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

March 2, 2023 | finance.yahoo.com

enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

February 8, 2023 | finance.yahoo.com

enVVeno Medical to Present at Cowen's 43rd Annual Health Care Conference

June 4, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

February 5, 2023 | yahoo.com

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

January 18, 2023 | finanznachrichten.de

enVVeno Medical Corporation: enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer

January 18, 2023 | finance.yahoo.com

enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer

January 11, 2023 | finance.yahoo.com

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

November 17, 2022 | finance.yahoo.com

Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues

November 7, 2022 | finance.yahoo.com

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

October 27, 2022 | finanznachrichten.de

enVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update

October 27, 2022 | finance.yahoo.com

enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update

October 14, 2022 | seekingalpha.com

NVNO enVVeno Medical Corporation

September 23, 2022 | seekingalpha.com

enVVeno Medical: Unique Exposure To Venous Treatment Domain

September 22, 2022 | finance.yahoo.com

enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference

September 21, 2022 | finance.yahoo.com

enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous Valve for the Treatment of Chronic Venous Insufficiency

September 19, 2022 | finance.yahoo.com

enVVeno Medical to Host Conference Call and Webcast on September 21, 2022

September 12, 2022 | finanznachrichten.de

enVVeno Medical Corporation: enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 12, 2022 | finance.yahoo.com

enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 29, 2022 | finance.yahoo.com

enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans

August 16, 2022 | finanznachrichten.de

enVVeno Medical Corporation: enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

August 16, 2022 | finance.yahoo.com

enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

See More Headlines

NVNO Price History

30 days | 90 days | 365 days | Advanced Chart

NVNO Company Calendar

Last Earnings: 8/11/2021
Today: 6/04/2023
Next Earnings (Estimated): 8/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NVNO
CUSIP: N/A
CIK: 1661053
Web: www.hancockjaffe.com
Phone: (949) 261-2900
Fax: 949-261-2992
Employees: 19
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,670,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.50%
Return on Assets: -59.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 29.58
Quick Ratio: 29.58

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.60 per share
Price / Book: 0.88

Miscellaneous

Outstanding Shares: 9,470,000
Free Float: 7,928,000
Market Cap: $29.93 million
Optionable: Not Optionable
Beta: 1.24

Key Executives

Robert Andrew Berman
Chief Executive Officer & Director

Craig T. Glynn
Chief Financial Officer & Treasurer

Marc H. Glickman
Chief Medical Officer & Senior Vice President

Hamed Alavi
Vice President-Research, Development & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NVNO Stock - Frequently Asked Questions

How have NVNO shares performed in 2023?: enVVeno Medical's stock was trading at $5.10 at the beginning of 2023. Since then, NVNO stock has decreased by 38.0% and is now trading at $3.16.
View the best growth stocks for 2023 here.
When is enVVeno Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our NVNO earnings forecast.
How were enVVeno Medical's earnings last quarter?: enVVeno Medical Corporation (NASDAQ:NVNO) released its earnings results on Wednesday, August, 11th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06.
What is enVVeno Medical's stock symbol?: enVVeno Medical trades on the NASDAQ under the ticker symbol "NVNO."

Who are enVVeno Medical's major shareholders?: enVVeno Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Susquehanna International Group LLP (0.46%) and Dimensional Fund Advisors LP (0.25%). Insiders that own company stock include Francis Duhay, Gmt Capital Corp, Holding SA Biodyne, Marc H Glickman, Matthew Jenusaitis, Robert Andrew Berman, Robert Gray and Sanjay Shrivastava.
View institutional ownership trends.
How do I buy shares of enVVeno Medical?: Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is enVVeno Medical's stock price today?: One share of NVNO stock can currently be purchased for approximately $3.16.
How much money does enVVeno Medical make?: enVVeno Medical (NASDAQ:NVNO) has a market capitalization of $29.93 million.
How can I contact enVVeno Medical?: enVVeno Medical's mailing address is 70 DOPPLER, IRVINE CA, 92618. The official website for the company is www.hancockjaffe.com. The company can be reached via phone at (949) 261-2900 or via fax at 949-261-2992.

This page (NASDAQ:NVNO) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial